ADMA (ADMA Biologics) Cyclically Adjusted Revenue per Share: $1.11 (As of Mar. 2026)


ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $8.95
GF Value $18.01
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Cyclically Adjusted Revenue per Share?

ADMA Biologics ADMA +3.95% 64 Cyclically Adjusted Revenue per Share is $1.11 as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.01 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ADMA Biologics's adjusted revenue per share for the three months ended in Mar. 2026 was $0.477. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.11 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ADMA Biologics's average Cyclically Adjusted Revenue Growth Rate was 14.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ADMA Biologics was 13.10% per year. The lowest was 6.10% per year. And the median was 11.25% per year.

As of today (2026-07-05), ADMA Biologics's current stock price is $8.95. ADMA Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.11. ADMA Biologics's Cyclically Adjusted PS Ratio of today is 8.06.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ADMA Biologics was 24.86. The lowest was 1.72. And the median was 5.00.


ADMA Biologics  (NAS:ADMA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ADMA Biologics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8.95/1.11
=8.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ADMA Biologics was 24.86. The lowest was 1.72. And the median was 5.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ADMA Biologics Cyclically Adjusted Revenue per Share Related Terms


ADMA Biologics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Cyclically Adjusted Revenue per Share Chart

ADMA Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.74 0.82 0.93 1.07

ADMA Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 1.01 1.05 1.07 1.11

ADMA vs ZLAB, HRMY, STOK: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, ADMA Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADMA Biologics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Cyclically Adjusted PS Ratio falls into.


ADMA
64GF Score
ADMA Biologics Inc ADMA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADMA Biologics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ADMA Biologics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.477/330.2130*330.2130
=0.477

Current CPI (Mar. 2026) = 330.2130.

ADMA Biologics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.187 241.018 0.256
201609 0.228 241.428 0.312
201612 0.258 241.432 0.353
201703 0.204 243.801 0.276
201706 0.207 244.955 0.279
201709 0.183 246.819 0.245
201712 0.265 246.524 0.355
201803 0.089 249.554 0.118
201806 0.109 251.989 0.143
201809 0.091 252.439 0.119
201812 0.087 251.233 0.114
201903 0.076 254.202 0.099
201906 0.126 256.143 0.162
201909 0.122 256.759 0.157
201912 0.203 256.974 0.261
202003 0.138 258.115 0.177
202006 0.090 257.797 0.115
202009 0.117 260.280 0.148
202012 0.144 260.474 0.183
202103 0.139 264.877 0.173
202106 0.140 271.696 0.170
202109 0.155 274.310 0.187
202112 0.146 278.802 0.173
202203 0.149 287.504 0.171
202206 0.173 296.311 0.193
202209 0.209 296.808 0.233
202212 0.246 296.797 0.274
202303 0.256 301.836 0.280
202306 0.270 305.109 0.292
202309 0.288 307.789 0.309
202312 0.327 306.746 0.352
202403 0.346 312.332 0.366
202406 0.443 314.175 0.466
202409 0.490 315.301 0.513
202412 0.474 315.605 0.496
202503 0.469 319.799 0.484
202506 0.491 322.561 0.503
202509 0.549 324.800 0.558
202512 0.572 324.054 0.583
202603 0.477 330.213 0.477

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.11 mean?
ADMA Biologics (ADMA) has a Cyclically Adjusted Revenue per Share of $1.11 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ADMA Biologics and its competitors.
Is ADMA Biologics' Cyclically Adjusted Revenue per Share too high?
ADMA Biologics' current Cyclically Adjusted Revenue per Share is $1.11. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Cyclically Adjusted Revenue per Share compare to ZLAB and HRMY?
ADMA Biologics' Cyclically Adjusted Revenue per Share of $1.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Cyclically Adjusted Revenue per Share is $1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.01, compared to a current price of $8.95 — trading 50.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.11. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Cyclically Adjusted Revenue per Share is $1.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.95 is trading 50.3% below its estimated GF Value™ of $18.01. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Cyclically Adjusted Revenue per Share: $1.11
  • GF Value™: $18.01 vs. price of $8.95 (50.3% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.95
Price
$18.01
GF Value